To:
`
`Subject:
`
`Chillemi, Michael (torourke@bodnerorourke.com)
`
`U.S. TRADEMARK APPLICATION NO. 85497733 - FUNCTIONAL
`EVALUATIONS - N/A
`
`Sent:
`
`11/25/2013 9:55:32 AM
`
`Sent As:
`
`ECOM116@USPTO.GOV
`
`Attachments: Attachment - 1
`Attachment - 2
`Attachment - 3
`Attachment - 4
`Attachment - 5
`Attachment - 6
`Attachment - 7
`Attachment - 8
`Attachment - 9
`Attachment - 10
`Attachment - 11
`Attachment - 12
`Attachment - 13
`Attachment - 14
`Attachment - 15
`Attachment - 16
`Attachment - 17
`Attachment - 18
`Attachment - 19
`Attachment - 20
`Attachment - 21
`Attachment - 22
`Attachment - 23
`Attachment - 24
`Attachment - 25
`Attachment - 26
`Attachment - 27
`
`UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO)
`OFFICE ACTION (OFFICIAL LETTER) ABOUT APPLICANT’S TRADEMARK APPLICATION
`
`(cid:160)
`

`
`(cid:160)(cid:160)(cid:160) U.S. APPLICATION SERIAL NO. 85497733
`
`(cid:160)(cid:160)(cid:160)(cid:160) MARK: FUNCTIONAL EVALUATIONS
`
`(cid:160)(cid:160)(cid:160) CORRESPONDENT ADDRESS:
`(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160) (cid:160)(cid:160) (cid:160)(cid:160) THOMAS A O'ROURKE
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) BODNER & O'ROURKE LLP
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) 425 BROADHOLLOW RD(cid:160) SUITE 120
`(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160)(cid:160)(cid:160) MELVILLE, NY 11747-4701
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`*85497733*
`
`CLICK HERE TO RESPOND TO THIS LETTER:
`http://www.uspto.gov/trademarks/teas/response_forms.jsp
`
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160) (cid:160)(cid:160) (cid:160)
`(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160) APPLICANT: Chillemi, Michael
`(cid:160) (cid:160)(cid:160)(cid:160)(cid:160)(cid:160) CORRESPONDENT’S REFERENCE/DOCKET NO :(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`(cid:160)(cid:160)(cid:160)
`
`(cid:160) (cid:160) N/A
`
`(cid:160)(cid:160)(cid:160) CORRESPONDENT E-MAIL ADDRESS:(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`
`(cid:160) (cid:160) torourke@bodnerorourke.com
`
`OFFICE ACTION
`
`ISSUE/MAILING DATE: 11/25/2013
`
`THIS IS A FINAL ACTION.
`
`This office action responds to the applicant’s request for reconsideration filed on October 15, 2013. (cid:160)
`Upon further review of the application file, an identification issue has come to the attention of the
`examining attorney and requires issuance of this subsequent final action.(cid:160) This action makes final the
`requirement for an acceptable recitation of services in addition to continuing the final generic refusal
`
`under Trademark Act Section 23(c) originally issued on April 11, 2013. (cid:160)(cid:160)
`
`Since a notice of appeal has already been filed, this application will be sent back to the Trademark Trial
`
`and Appeal Board to resume the appeal immediately following issuance of this subsequent final action.(cid:160)(cid:160)
`
`RECITATION OF SERVICES – FINAL
`
`(cid:160)O
`
`n February 13, 2013, the applicant amended the recitation of services from “Medical diagnostic
`services, namely, testing, monitoring and reporting, for the legal and medical community,” in
`International Class 44 to “Medical diagnostic services, namely, testing, monitoring and reporting, for the
`legal and medical community acting as experts in legal matters” with the added language shown in italics.
`(cid:160) This identification amendment is rejected as being outside the scope.
`
`(cid:160)N
`
`otice was given that identifications of services can be amended only to clarify or limit the services;
`adding to or broadening the scope of the services is not permitted.(cid:160) 37 C.F.R. §2.71(a); see TMEP
`§§1402.06 et seq., 1402.07.(cid:160) Therefore, applicant may not amend the identification to include services that
`are not within the scope of the services set forth in the present identification.
`
`(cid:160)T
`
`he wording "acting as experts in legal matters" includes expert witness services in legal matters" which is
`a service classified in International Class 45.(cid:160) Appearing as an expert witness is outside the originally-
`
`(cid:160)(cid:160)
`(cid:160)(cid:160)
`(cid:160)
`

`
`claimed medical diagnostic services in International Class 44.(cid:160) These added services are beyond the scope
`of the original identification.(cid:160) Applicant may substitute the following wording, if accurate:(cid:160) “Medical
`diagnostic services, namely, testing, monitoring and reporting, for the legal and medical community,” in
`International Class 44.
`
`(cid:160)T
`
`he amendment is rejected and the requirement for an acceptable recitation of services is made final.
`
`(cid:160)C
`
`ONTINUED FINAL REFUSAL
`
`(cid:160)M
`
`ARK IS GENERIC - FINAL
`
`(cid:160)R
`
`egistration is refused on the Supplemental Register because the applied-for mark is generic and thus
`incapable of distinguishing applicant’s services. (cid:160) Trademark Act Section 23(c), 15 U.S.C. §1091(c); see
`TMEP §§1209.01(c) et seq.
`
`(cid:160)D
`
`etermining whether a mark is generic requires a two-step inquiry:
`
`(1)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160) What is the genus of services at issue?
`
`(cid:160)(
`
`Does the relevant public understand the designation primarily to refer to that genus of
`2)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)(cid:160)
`services?
`
`(cid:160)I
`
`n re 1800Mattress.com IP, LLC, 586 F.3d 1359, 1363, 92 USPQ2d 1682, 1684 (Fed. Cir. 2009) (quoting
`H. Marvin Ginn Corp. v. Int’l Ass’n of Fire Chiefs, Inc., 782 F.2d 987, 989-90, 228 USPQ 528, 530 (Fed.
`
`Cir. 1986)); TMEP §1209.01(c)(i).(cid:160)(cid:160)
`
`Regarding the first part of the inquiry, the genus of the services is often defined by an applicant’s
`identification of services.(cid:160) See, e.g., In re Reed Elsevier Props. Inc., 482 F.3d 1376, 1379, 82 USPQ2d
`1378, 1380 (Fed. Cir. 2007); Magic Wand Inc. v. RDB Inc., 940 F.2d 638, 640, 19 USPQ2d 1551, 1552
`
`(Fed. Cir. 1991).(cid:160)(cid:160)
`
`In the present case, the identification and thus the genus, is “medical diagnostic services, namely, testing,
`
`monitoring and reporting, for the legal and medical community.” (cid:160)(cid:160)
`
`The previously attached definitions show that the wording FUNCTIONAL means “affecting
`physiological or psychological functions but not organic structure,” and EVALUATION is “to determine
`the significance, worth, or condition of usually by careful appraisal and study.” (cid:160) Based on dictionary
`definitions, the wording FUNCTIONAL EVALUATIONS means a determination made on the condition
`of one’s physiological or psychological function. (cid:160) This wording is used generically throughout the legal
`and medical community to identify testing to determine a person’s level of ability to function. (cid:160) See
`attached and previously attached evidence.(cid:160) The applicant performs this type of medical testing service to
`determine a person’s abilities. (cid:160) See attached website. Therefore, due to widespread generic usage of the
`mark FUNCTIONAL EVALUATIONS and the applicant’s own usage, the relevant public would
`
`understand this designation to refer primarily to that genus of services.(cid:160)(cid:160)
`
`In response, the applicant notes, "[W]e would like to point out that there is no definition of functional
`evaluations in the dictionary.” (cid:160) The fact that the wording is not in the dictionary is not controlling.(cid:160) Any
`term that the relevant public understands to refer to a particular genus of goods and/or services is generic;
`thus there can be more than one generic term for a particular genus.(cid:160) In re 1800Mattress.com IP, LLC, 586
`
`(cid:160)
`

`
`F. 3d 1359, 1364, 92 USPQ2d 1682, 1685 (Fed. Cir. 2009).
`
`(cid:160)T
`
`he applicant argues, “The mark FUNCTIONAL EVALUATIONS does not describe these services and
`is not understood by the relevant public primarily to refer to medical diagnostic services for the legal and
`medical community.” (cid:160) See Response.
`
`(cid:160)T
`
`he examining attorney disagrees.(cid:160) The attached and previously attached evidence demonstrates that the
`phrase FUNCTIONAL EVALUATIONS has an understood meaning in both the legal and medical
`community.(cid:160) See sample excerpts below.
`
`On Findlaw.com for Legal Professionals in an article entitled “Functional outcome evaluation of
`the head injured: Its Effect on Legal Rights:” (cid:160) “In conclusion, the growing area of functional
`evaluation will validate rehabilitation efforts and greatly improve the legal rights of persons with
`head injury.”
`
`(cid:160)O
`
`n Leadingedgephysio.com:(cid:160) “If you or your client has sustained an injury and are in need of
`return to work planning, work modification suggestions, legal interpretation of the impact of injury
`and/or recommendations regarding ongoing rehabilitation, perhaps a functional evaluation would
`be useful.”
`
`(cid:160)O
`
`n ISR-institute.com:(cid:160) “ISR Institute provides nationwide, job specific, ADA compliant
`functional evaluations on employee applicants before job assignment…and for return to work of
`existing employees…following injury, illness or change in safe work capacity status.”
`
`(cid:160)O
`
`n Phiphysio.com under Title “Functional Abilities Evaluation:” (cid:160) “Baseline Evaluation: This
`objective, functional evaluation is completed to establish a starting point for rehabilitation and
`allows each program to be specifically and accurately customized.”
`
`(cid:160)F
`
`rom the attached and previously attached evidence, it is clear that the mark is used in a generic fashion in
`both the legal and medical community and therefore, the relevant public would understand the designation
`
`to primarily refer to the genus of applicant’s services. (cid:160)(cid:160)
`
`The applicant’s request for reconsideration presents no new issues or evidence and therefore, is denied. (cid:160)
`In its Request for Reconsideration, the applicant referred to and attached multiple copies of third party
`registrations containing either the term FUNCTIONAL or EVALUATION on the Principal Register to
`support its contention that the proposed mark should be registered.(cid:160) See Request for reconsideration filed
`
`October 15, 2013.(cid:160)(cid:160)
`
`The fact that third-party registrations exist for marks allegedly similar to applicant’s mark is not
`conclusive on the issue of descriptiveness.(cid:160) See In re Scholastic Testing Serv., Inc., 196 USPQ 517, 519
`(TTAB 1977); TMEP §1209.03(a).(cid:160) An applied-for mark that is merely descriptive (or generic) does not
`become registrable simply because other seemingly similar marks appear on the register.(cid:160) In re Scholastic
`Testing Serv., Inc., 196 USPQ at 519; TMEP §1209.03(a).
`
`(cid:160)I
`
`t is well settled that each case must be decided on its own facts and the Trademark Trial and Appeal
`Board is not bound by prior decisions involving different records.(cid:160) See In re Nett Designs, Inc., 236 F. 3d
`1339, 1342, 57 USPQ2d 1564, 1566 ( Fed. Cir. 2001); In re Lean Line, Inc., 229 USPQ 781, 783 (TTAB
`1986); TMEP §1209.03(a).(cid:160) The question of whether a mark is merely descriptive is determined based on
`the evidence of record at the time each registration is sought.(cid:160) In re theDot Commc’ns Network LLC, 101
`USPQ2d 1062, 1064 (TTAB 2011); TMEP §1209.03(a); see In re Nett Designs, Inc., 236 F.3d at 1342, 57
`
`(cid:160)
`

`
`USPQ2d at 1566.
`
`(cid:160)T
`
`he mark FUNCTIONAL EVALUATIONS is generic and therefore, refusal under Trademark Act
`Section 23(c) is maintained and made final.
`
`(cid:160)A
`
`pplicant cannot overcome this refusal by submitting a claim of acquired distinctiveness under Trademark
`Act Section 2(f).(cid:160) See 15 U.S.C. §1052(f).(cid:160) Such a claim would be insufficient because no amount of
`purported proof that a generic mark has acquired secondary meaning can transform it into a registrable
`trademark or service mark.(cid:160) See In re Bongrain Int’l Corp ., 894 F.2d 1316, 1317 n.4, 13 USPQ2d 1727,
`1728 n.4 (Fed. Cir. 1990); H. Marvin Ginn Corp. v. Int’l Ass’n of Fire Chiefs, Inc., 782 F.2d 987, 989,
`228 USPQ 528, 530 (Fed. Cir. 1986); TMEP §1212.02(i).(cid:160) A generic term cannot become a trademark or
`
`service mark under any circumstance.(cid:160)(cid:160) (cid:160)
`
`/Barbara Brown/
`Trademark Examining Attorney
`Law Office 116
`TEL: 571-272-9134
`FAX: 571-273-9116
`barbara.brown@uspto.gov
`
`(cid:160)T
`
`O RESPOND TO THIS LETTER: (cid:160) Go to http://www.uspto.gov/trademarks/teas/response_forms.jsp. (cid:160) Please
`wait 48-72 hours from the issue/mailing date before using the Trademark Electronic Application System
`(TEAS), to allow for necessary system updates of the application.(cid:160) For technical assistance with online
`forms, e-mail TEAS@uspto.gov.(cid:160) For questions about the Office action itself, please contact the assigned
`trademark examining attorney.(cid:160) E-mail communications will not be accepted as responses to Office
`actions; therefore, do not respond to this Office action by e-mail.
`
`(cid:160)A
`
`ll informal e-mail communications relevant to this application will be placed in the official
`application record.
`
`(cid:160)W
`
`HO MUST SIGN THE RESPONSE:(cid:160) It must be personally signed by an individual applicant or
`someone with legal authority to bind an applicant (i.e., a corporate officer, a general partner, all joint
`
`applicants).(cid:160) If an applicant is represented by an attorney, the attorney must sign the response.(cid:160)(cid:160)
`PERIODICALLY CHECK THE STATUS OF THE APPLICATION: (cid:160) To ensure that applicant does
`not miss crucial deadlines or official notices, check the status of the application every three to four months
`using the Trademark Status and Document Retrieval (TSDR) system at http://tsdr.uspto.gov/. (cid:160) Please keep
`a copy of the TSDR status screen. (cid:160) If the status shows no change for more than six months, contact the
`Trademark Assistance Center by e-mail at TrademarkAssistanceCenter@uspto.gov or call 1-800-786-
`9199. (cid:160) For more information on checking status, see http://www.uspto.gov/trademarks/process/status/.
`
`(cid:160)T
`
`O UPDATE CORRESPONDENCE/E-MAIL ADDRESS:(cid:160) Use the TEAS form at
`http://www.uspto.gov/trademarks/teas/correspondence.jsp.
`
`(cid:160)(cid:160)
`

`
`Functional
`—
`Evaluations
`w\~‘wiFunctionalEva|Liation-3‘com
`
`MY ACCO
`
`T
`
`mu
`Free)
`
`1-
`
`335
`
`4040
`
`http:i'i'www.functionalevaluationscomil
`
`1ii'25i'2013 08:53 00 AM
`
`
`
`
`
`Home WhatisaFE? Why Order? When
`To Order?
`
`
`
`Available Profiles
`
`Benefits
`
`Legal_fMeciica|
`
`Track Patient Progress
`
`An Innovative Appficatian of
`
`Functional Evaluation Testing
`
`in
`
`"'
`
`1,
`. ‘
`'
`' Q
`-' _,"
`
`‘
`
`a Proven Functional
`Diagnostic Technology
`u Objective Evidence—Ba5ed Medicine
`0 Establish Medical Necessity for
`Treatment
`
`I Track Patient Progress
`
`I quantify Positive Patient Response
`
`I Qualify Variances
`
`u Legally Defensible Documentation for
`Litigation
`
`
`
`We would like to introduce you to our computerized Functional Evaluation SEl'VlCES provided by FunctionalEvaluations.com. The
`purpose of a Functional Evaluation is to evaluate the beginning stages of your patient’s care and then track your patient's
`progress throughout all subsequent stages of care. Tl'l|S test will help you evaluate whether or not a patient's treatment plan is
`EiTEClflVE, or if it needs to be modified.
`
`

`
`httpzffwww.functionalevaluatiohscomf
`
`11f25f2013 08:53 00 AM
`
`We provide a mobile service by sending one of our Technologists to your office to perform the evaluation. Using our patent-
`pending custom software, this data will provide you with comprehensive graphic and textual reports. This will enable you to
`objectively support the patient's diagnosis, provide information for deposition reports, and assist you in providing disability
`ratings.
`
`The Objective Truth
`
`Functiona|Eva|uations.com provides data reports that allow you to make medically necessary decisions based on the patient's
`best interest. W'ith patented technology, Funcliona|Eva|uations.com can objectively identify when an individual is
`misrepresenting their true physical abilities with a high level of confidence. After a decade of research and development, a panel
`of leading independent medical experts has agreed that Functiona|Eva|uations.com offers an unprecedented tool for making
`these important determinations.
`Superior Protocol
`
`We guarantee each Functional Evaluation achieves the highest standard of excellence. our dedicated full—time staff has received
`the most extensive training currentiy available for Functional Evaluations. Dur computerized system applies technology to the
`standardized tests. This provides an increase in reliability, as well as ease of evaluator reporting. We deploy our exclusive
`technology——the only technology proven in thousands of examinations from our research——to deliver the most accurate
`information for sound claims and better decision making.
`Valuable Rfiults
`
`Functional Evaluations are an excellent means of quantifying the effectiveness of treatment. Our diagnostic reports are a great
`resource for documentation. They serve in providing an accurate diagnosis of a patient's problem area(s), as well as an
`objective viewpoint for baseline and ongoing patient status. The value derived from Functional Evaluation testing is
`immeasurable.
`
`Convenience of In-Office Testing
`Physicians recognize the importance of Functional Evaluation testing in their offices but may be concerned with the negative
`reputation associated with non—professiona| “medical providers.” We are committed to providing physicians with top—tier
`Functional Evaluation testing, while maintaining unmatched quality of patient care. No matter where you are located,
`FunctionalEva|uations.com will bring our testing services to your office. 0n—site testing serves as a convenience for physicians,
`as well as patients. These tests are non—invasive and patient friendly. Patients are, and should remain, our top priority.
`Experience Ii Reputation
`
`Since 2I]I]1, we have continued to deliver the most objective and comprehensive functional testing available. Our reputation is
`most important. We do not provide any other service that could compromise the integrity of our evaluations. We are dedicated
`to providing Functional Evaluation Services with the most advanced technologies and research available. We stake our
`reputation on each Functional Evaluation we perform.
`Critical Illfunlldliun
`
`To appropriately adjudicate a claim it is essential to use a Functional Evaluation that providfi an accurate and unbiased dinioal
`understanding of a patient's true physical ability. Without this objective information inappropriate daim decisions may result in
`an increased loss of time, unnecessary treatment, and an opportunity to abuse the claims process. This is unacceptable for all
`parties who expect an equitable resolution of a claim.
`Legaly Defensible
`
`If it is not defensible, do not use it. W'ith over a decade of research and development our technology delivers a defensible
`Functional Evaluation which consistentiy proves itself in the most litigious jurisdictions in the United States. This technology has
`been identified by and upheld in the court system.
`If you have any questions or would like to schedule tfiting, please call (666) 335-4040.
`
`

`
`httpzffeurihf. oxfordiournals.0rcifc0ntentr'5i'3f24?.5hoit
`
`1li'25il2013 08:53 52 AM
`
`DKFCZI RD J D l_| R N AL-‘.7
`
`
`European Journal of Heart allure Institution: uspto Sign In as Personal Subscriber
`
`
`Oxford Journals» Medicine: European Journal of Heart Failure: Volume 5, Issue 3 3 Pp. 242-252.
`<< Previous | Next Article :
`Table of Contents
`
`Prognostic value of 6-minute walk
`
`1
`
`corridor test in patients with mild to
`
`moderate heart failure: comparison
`with other methods of functional
`
`evaluation
`
`Carlo Rostagno‘, Giuseppe Olivo, Marco Comeglio, Vieri Boddi,
`Michela Banchelli, Giorgio Galanti and Gian Franco Gensini
`+ Author Affiliations
`
`‘Corresponpin author, U.O. Clinicallvledica e C rdiologia Universitéi di
`Firenze, Via e
`orgagni 85. 50134 F orence. lta 3:. Te .: +3'9—S5—-12??'5i 8;
`fax: +3‘3—55—42 }'75?8. E—mail address: c. rostagno@katarnai|.corri
`Received April 26. 2001.
`Revision received March 11,2002.
`Accepted May 29, 2002.
`
`Abstract
`
`Aim: The study was designed to evaluate the prognostic
`value of the 6—min walk test (BMWT) in patients with mild
`to moderate congestive heart failure (CHF).
`
`Aboulrhe liidex a
`patients (H9 men and 95 women, mean age 64 years)
`were followed for a mean period of 34 months to assess
`event—free survival (death, heart transplantation). Sixty-
`six patients (3496) died (63 cardiovascular causes, 2 cancer
`and I stroke) and five patients undenivent heart
`transplantation. For patients who walked <300 m during
`the 6MWT, survival was 62% compared with 82% in
`patients who walked 300—450 in or>450 in. with
`univariate analysis, NYHA class was the strongest
`predictor of death. LVEF (P<0.000l), aetiology of heart
`
`This Article
`
`Eur] Heart Fall (2003) 5
`(3): 247-252.
`doi: 10.1016/51.383-9842
`(O2)00244-1
`» Abstract Free
`Full Text (HTML) Free
`Full Text (PDF) Free
`- Classifications
`
`Articles
`
`- Services
`Alert me when cited
`Alert me if corrected
`Find similar articles
`Similar articles in PubMed
`Add to my archive
`Download citation
`Request Permissions
`Disstsimsr
`Show related llI1l(S
`,, W ,1
`
`;".-Gorrgleuscholar
`+ Publled
`' Share
`
`E lEl -'
`What's this?
`
`V
`
`Oxford Ines?
`
`Search this journal:
`
`Aclva ncecl »
`Current Issue
`
`December 2013 15 (12)
`
`W
`
`fl“
`
`Heart Failure
`
`Alert me to new issues
`
`Sign In to Submit
`
`The Journal
`
`About the journal
`Rights & permissions
`Corporate Services
`We are mobile — find out
`more
`
`Search across all sources
`--~-- --rr
`
`ir' l:l.\l3|'§ India
`
`lE$CJournals
`
`Download the new App
`now
`
`Editors
`Edii;u'r—"in—(':'h'i'ef
`Prof. Dr. Dirk J. van
`Veldhuisen
`
`

`
`httpzffeurihf. oxfordlournals.0rcifcontenl;i'5i'3f24?.shoit
`
`1lf25r’2013 08:53 52 AM
`
`Oxford indéi‘
`
`Oxford inciéS'€
`
`failure (P<0.00l), LV filling pattern (P=0.002) and EMWT
`distance (P<0.0l) were all significantly related to survival.
`No significant relationship was found between survival,
`r1tl'1Ir nu. 1:111-vn rrlvlrllrv-r\+:r|I1
`':lI'l"lrlrr||'\:r +L.r..rl~.nIA
`Abouithe lrirlex.
`Ivlulllvclllcuc clllcllyolo uolllg Lllc \_.UA—:.ncp\"rI:.iC Icglcoalull
`
`model showed that LV fractional shortening (P<0.009)
`and EMWT distance (P<0.0005) were the strongest
`prognostic markers.
`
`Conclusion: A EMWT distance of <300 m is a simple and
`useful prognostic marker of subsequent cardiac death in
`unselected patients with mild to moderate CHF.
`
`Keywords Heart failure aPrognosis nFunctiona| evaluation
`
`© 2002 European Society of Cardiology
`
`Articles citing this article
`Aboui the lndex U
`Aerobic exerche intensity assessment and prescription in
`cardiac rehabilitation: in joint position statement of the
`European Association for Cardiovascular Prevention and
`Rehabifitation. the American Association of Cardiovascular
`and Puimonary Rehabfitation and the Canadian Association
`of Cardiac Rehabilitation
`Europaar Journal of Prevertive Cardiology (20131 23 (3): 44246?
`>vAbstract »Full Text (HTML) »FuEl Text (PDF)
`
`Many nfiponse criteria are poor predictors of outcomm after
`cardiac resynchronization therapy: vaidation using data from
`the randomized trial
`Europace (201.3)-15 (6]-: 335-844
`>vAbstract »FulI Text (HTML) »Full Text (PDF)
`
`An 0pen—Label Dose Escalation Study to Evaiuate the Safety
`of Adminiitration of Honviral Stromal Ce!-Derived Factor-1
`
`Oxford Innis‘?
`
`About the lndex U
`
`>vAbstract »Full Text (HTML) »Full Text (PDF)
`
`Show related lri: ks
`
`Increased Tricuspid Regurgitant Jet Vdocity by Doppler
`Echocardiography in Adult Survivors of Childhood Cancer: A
`Report From the St Jude Lifetime Cohort Study
`Jco (2513) 3-«_ (5): 774-731
`M Aka!-rah? M Eiill Tn\ri'
`i'|—lTMI \ M Eiill Tnv+ i'DF\I?\
`
`» View all Most Read
`articles
`
`Show related links
`
`:r- C.‘)o_fo rd In den
`
`Vlifll II LIEBII
`
`View full editorial board
`
`For Authors
`Search across alsolirtes
`Services for authors
`Self archiving policy
`Submit now!
`
`f‘)l='F'l\.|
`OXFORD‘
`Open access options for
`authors visit Oxford
`Open
`
`ii
`Email table of contents
`CiteTrack
`XML RSS feed
`
`Show related‘ lln ks
`
`Search xzruss al suimes in Cxford lrdex
`
`’
`
`i Left bundle branch
`block as a risk
`factor for
`progression to
`heart failure
`'Frequent'
`ventricular bigeminy
`— A reversible cause
`of dilated
`cardiomyopathy.
`How frequent is
`'frei:iuent'?
`1“ The management of
`hyperuricemia and
`gout in patients
`with heart failure
`F Alcohol abuse and
`heart failure
`Fluid overtoad in
`ar‘III'n hcmi-I’ F-ailuirn _
`Searcliaeroasalsuircea
`i:ll|U ULIIBI
`mechanisms beyond
`fluid accumulation
`
`P
`
`.I‘ Oxford index
`
`

`
`httpzffeurihf. oxfordlournals.0rcifc0ntente'5f3f24?.5hoI‘t
`
`1lf25!2013 08:53 52 AM
`
`>vAbstract » Full Text (HTML) » Full Text (PDF)
`
`Silrminute walking tat but not ejection fraction predicts
`mortaity in elderly patients undergoing cardiac rehabiitation
`folowing coronary artery bypass grafting
`European Journal of Preventive C‘arclIo|og‘r(20L2]19(E]I: L-1014409
`>vAbstract »Full Text (HTML) »FuII Text (PDF)
`
`Oxford Ind€S'€
`
`The Elilin Walk Test: is It an Effective Method for Evaluating
`Heart Failure Therapies!
`About the lndex B
`N Abstract N Full Text (PDF)
`
`Show related Em ks
`
`Search across H sources
`
`In Dxfurd Index
`
`Repeat six-minute walk tests in patients with chronic heart
`faiure: are they cinically necifisary?
`European Journal of Preventive Carcliology (2EIL1j 13 (4): 501-505
`»Abstract » Full Text (HTML) » Full Text (PDF)
`
`The 6—min walk distance in healthy subjects: reference
`standards from seven countries
`Eur RespirJ (2011) 3? (L): 150-155
`>vAbstract »Fu|| Text (HTML) »Fu|I Text (PDF)
`
`Ettecm of cardiac raynchronisation therapy in patienu with
`heart faiure having a narrow QRS Complex enrolled in
`PROSPECT
`Heart (2010) 96 (14): 1107-1113
`
`Oxford Inda‘?
`
`About the mole: U
`
`Show related In: K:
`
`Search across all source!
`
`In Dxfurd Index
`
`Exercise testing in the prognostic evaluation of patients with
`lung and heart diseascs
`Clinical Exercise Testing (201,) 1(1): 195-207
`»Abstract » Full Text (HTML) » Full Text (PDF)
`
`Walking for the assessment of patients with chronic
`obstructive pulmonary dse
`Clinical Exercise Testing (2010) L (1): 140-154
`>vAbstract »Full Text (HTML) »FuII Text (PDF)
`
`Detectable Changes in Physical Performance Measures in
`Elderly African Americans
`ptjournal (2C;0) 90 (6): 921-927
`nAbstmct n Full Text (HTML) n Full Text (PDF)
`
`Oxford Ines‘?
`
`Aboutthelndex B
`IO IZIINJSCDTE In FIBIIIEIIE undergoing BOFIIIC VEIIVE replacement
`Hear‘t (2010) 96 (2): ‘.13-L1?
`
`Show related Fill ks
`
`Search across all sources
`
`in Oxford Index
`
`

`
`httpzffeurihf. o><f0rd\0uma\5.0rqfc0ntentf5f3f24?.5hort
`
`11f25!2013 08:53 52 AM
`
`Oxford Ind.-S2
`
`>vAbstract » Full Text (HTML) » Full Text (PDF)
`
`Six—minute walk tat: independent prognostic marker?
`Heart (2013) 96 (2): 97—93
`» Fuii Text (HTML) » Full Text (PDF)
`
`What is treatment succfi in cardiac resynchronization
`therapy?
`Eurupate (2399:. 11(.§.LIpp|_5): U53-U55
`NAbstra::t NFUII Text (HTML) NFUII Text (PDF)
`
`A Review of the Six-Minute Walk Test: Its Impfication as a
`Sdf—Admin'E.'tered Assessment Tool
`Eur] Car-tlinvasc Nurs (2859) S (3): 232-235
`Ahnul Nae ‘rider 5
`
`A Review of the Six-Minute Walk Test: Its Implication as a
`Self-Adminktered Assessment Tool
`Eur] Car\:|im'a5: Nurs (2339) 3 (L): 2-3
`NAbstra::t me Full Text (HTML) n Full Text (PDF)
`
`Physical Function in Older Candidatfi for Renal
`Transplantation: An Impaired Population
`CJASN (2509) 4 (3): 533--sen
`>vAbstract » Full Text (HTML) » Full Text (PDF)
`
`Six-minute walking test predicts long-term cardiac death in
`patienu who received cardiac rifiynchronization therapy
`Eurapace (2009) 11 (3): 338-342
`>vAbstract »Fu|| Text (HTML) »FuE| Text (PDF)
`
`Show relaled III! ks
`
`Sleolrrll :I:rn!15 Ii SIIIIIIZESI
`
`irI Dxfo rd Index
`
`Oxford Inda'iS'€
`
`About the Vndex U
`fledrl rdllure I-'dl.II:lIl.'i wull Lell. vI:lII.rlI;uIu:Ir byslullc
`Dysfunction
`Eu:'J Cardiovasc Nut-5 (20031 7-‘ (4-1: 303-305
`>vAbstract »Fu|| Text (HTML) »Fu|I Text (PDF)
`
`Show rehated Em ks
`
`Searchaeroasalsources in Oxford Index
`
`Prevalence and Treatment Patterns of Physical lmpairmenb
`in Patients “fith Metastatic Breast Cancer
`JCD (2533) :5 (ts): 2621-2629
`mbstract » Full Text (HTML) » Full Text (PDF)
`
`Assessment of Functional (npacity in Gfinical and Research
`Settings: A Sdentific Statement From the American Heart
`Association Committee on Exercise, Rehabiitation, and
`Prevention of the Counci on Cinical Cardiology and the
`Pnunril nn l"‘:|r.rIinu:u:rul:nr llnrninn
`
`

`
`httpzffeurihf. o><f0rd\0urna\5.0rqfc0ntentf5f3f24?.5hort
`
`11f25!2013 08:53 52 AM
`
`Oxfocdlnda-3?
`
`Counci on Cardimrascular Nursing
`Circulation (2007) 116 (3): 329-343
`so Full Text (HTML) 1- Full Text (PDF]
`Aluxflfliehniel H
`IIOOIOI
`Prognostic value of the 5 min walk test and 9elf—p-ereeived
`symptom severity in older patients with chronic heart fflure
`Eur Heart J (zoo?) 23 (5): 560-565
`ambstract I-Full Text (HTML) I-Full Text (PDF)
`
`Recommendations on the use of exerche testing in cinical
`practioe
`Eur Rapir J (2007) 29 (1): 185-209
`»Abstract I-Full Text (HTML) I-Full Text (PDF]
`
`Six ninute will: tat
`Eur Heart J (zoos) 26 (20): 2269
`a Full Text (HTML) » Full Text (PDF]
`
`Stlnwrelnizediflrst
`
`Seuclllcrossflallites irioxrmdhclex
`'
`
`Oxfardlndfii
`
`The reproducibity and sensitivity of the 6-nin wflk tfit in
`elderly patients with chronic heart Iaiure
`Alxlrlllnzhnlel I
`»Kt>s.tract »tuirIext(HTME) »tuirIe:¢(PDF)
`
`IIIIIII
`
`9-n-reininniie;
`
`-
`
`_
`seueiu-zuxnls-nan hoxfuditlex
`
`Relationship of Plasma Homocysteine with the Severity of
`Chronic Heart Fflure
`Clin. Chem. (zoos) 51 (3): 1512-1515
`a Full Text (HTML) » Full Text (PDF]
`
`Effect of candaartan on New York Heart Association
`functionii class: Ilesults of the Candi-sartan in Heart faiure:
`Assmnent of Reduction in Ilortiity and morbidity (CHARM)
`programme
`Eur Heart] (2004) 25 (21): 1921'.k1926
`»Abs.tract »FuII Text (HTML) »FuII Text (PDF]
`
`Desdaimer: Please note that abstracts for content pubiished before 1996 were created through digital scannin and may therefore
`not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but t e Pubisher wil not
`be heicl responsible for any remaining inaccuracies. if you require any further darification, pfiease contact our Customer Services
`
`Alxilrlttlehidel
`Onine ISSN 1879-0844 — Print ISSN 1388-9842
`
`cocoons
`
`seuuuuussalsu-we snoxrmdimiex
`nnumumeuin¢s—
`Copyright © 2013 European Society of Cardiology I
`
`Lm1vr.n_s1'r1' rrusss
`
`
`
`Alxxrlflielniel
`
`‘
`
`IOCICOI
`
`smuremenim:
`
`seamuemssalmunes snoxraadundex
`
`oxfo¢u|nug‘£
`
`ux1=o¢u|n¢g';'£
`
`

`
`httpzffonlinelibrarywilev c0mfcloiMO 1002i'hed.2890080104i'abstract
`
`’l1i'25f2013 08:55:04 AM
`
`Wiley Online Library
`
`«I-
`Log in i
`Register
`
`0
`
`We made research easy.
`Now we make job hunting easy.
`P~3:flWtLEY Job Network
`
`.
`
`rr - R'Ec3I$'lEl'~‘
`' .
`T0|:I.A'i-‘u
`
`Home > Surgery 8. Surgical Specialties > Surgery 8. Surgical Specialties > Head Br Neck Surgery > Vol B Issue 1 > Abstract
`
`H 1:-rttt)
`N'=E?i:i<
`Article
`
`New test series for the functional evaluation of oral cavity cancer
`John Teichgraeber MD‘ Julia Bowman MA,
`Issue
`SP—CCC, Professor Dr. Helmulh Goepiert
`MD Chairmarf
`_
`_
`Anicle first published online 18 JUL 2006
`DO|' 1{).1UD2.thed 28Q[}D8[l1D4
`
`JOURNAL OF THE SCiENCES AND SPEClttLTlES OF THE HEAD AND NECK
`
`
`lmms issue
`_
`
`in
`
`0
`Advanced a Saved Searches >
`
`I O Q
`
`AR-I-ICLE 1-BOLS
`Get PDF (842K)
`Save to My Pronie
`E-mall Unit to this Article
`‘fir. Export Citation rot this Article
`Get Citation Alerts
`Request Pennissions
`
`i Q
`
`Share E
`
`"'2 Get PDF (342K)
`
`Head 8; Neck Surgery
`Volume 8. Issue 1‘ pages 9-
`20 semgmbel-tougher 1935
`
`'
`
`E
`5
`fl
`6
`
`
`
`
`____
`
`_
`Actciiiionel Information (Show All}
`How to Cite Authorlnforrnation Publication History
`
`References
`
`cited By
`
`Abstract
`There are few studies that have addressed themselves to measuring speech. swallowing function and the ‘quality of life” of patients that have
`been treated for oral cavity cancer. The goal of this study was to develop a test series to assess the oral cavity fLinction and the general
`health of patients treated for oral cavity cancer. The results of 51 patients treated for oral cavity cancer will be compared by the site and stage
`of the lesion, as well as by treatment mode. In addition, the functional results achieved by different reconstructive techniques in the orai cavity
`will be presented. Radiotherapy patients as a group have the best speech and swallowing function while the patients treated with combined
`therapy have the worst function in the surgical group, those patients treated with intraoral skin grafts had the best speech results and those
`with primary closures had the best sw